Thailand Transthyretin Amyloid Cardiomyopathy Registry

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: t
View:

• Age \> 18 years.

• All patients diagnosed with ATTR-CM (Transthyretin cardiomyopathy) who have either symptomatic or asymptomatic must have evidence of cardiac involvement by echocardiogram as defined by left ventricle wall thickness of ≥ 12 mm and with at least one of the following criteria:

• Positive scintigraphy by 99mTC-DPD \[99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mTC-PYP \[Pyrophosphate\] or 99mTC-HMDP \[hydroxymethylene diphosphate\] with Perugini grade ≥ 2 and/or H/CL (heart to contralateral lung) ratio \> 1.5

• Positive scintigraphy by 99mTC-DPD \[99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mTC-PYP \[Pyrophosphate\] or 99mTC-HMDP \[hydroxymethylene diphosphate\] with Perugini grade 1 and positive cardiac biopsy tissue confirmed which Congo red stain ≥ 4 sites

• Positive scintigraphy by 99mTC-DPD \[99mTC-3,3-diphosphono-1,2-propano-dicarboxylic acid\] or 99mTC-PYP \[Pyrophosphate\] or 99mTC-HMDP \[hydroxymethylene diphosphate\] with Perugini grade 1 with positive non-cardiac biopsy tissue confirmed by Congo red stain

• Abnormalities on CMR (Cardiac MRI) \[Subendocardium LGE (late gadolinium enhancement) and/or elevated native T1 value and/or increased extracellular volume (ECV \> 0.4)\] with positive non-cardiac and/or cardiac tissue biopsy confirmed by Congo red stain

Locations
Other Locations
Thailand
Faculty of Medicine at Chulalongkorn University
NOT_YET_RECRUITING
Bangkok
Faculty of Medicine Ramathibodi hospital, Mahidol University
NOT_YET_RECRUITING
Bangkok
Faculty of Medicine Siriraj Hospital, Mahidol University
NOT_YET_RECRUITING
Bangkok
Phramongkutklao Hospital
NOT_YET_RECRUITING
Bangkok
Faculty of Medicine Chiang Mai University
NOT_YET_RECRUITING
Chiang Mai
Queen Sirikit Heart Center of The Northeast
NOT_YET_RECRUITING
Khon Kaen
Faculty of Medicine, Thammasat University
NOT_YET_RECRUITING
Pathum Thani
Prince of Songkla University
RECRUITING
Songkhla
Contact Information
Primary
Kanchalaporn Jirataiporn, B.N.S.
kanchalaporn.jir@mahidol.ac.th
0635153519
Time Frame
Start Date: 2024-07-30
Estimated Completion Date: 2030-06-30
Participants
Target number of participants: 105
Treatments
ATTR Cardiomyopathy
Patients diagnosed with ATTR-CM (Transthyretin cardiomyopathy)
Sponsors
Collaborators: Pfizer
Leads: Mahidol University

This content was sourced from clinicaltrials.gov

Similar Clinical Trials